Why the study?
Patients with NAFLD have an increased risk of structural and functional cardiovascular disease, but whether an association exists between NAFLD and valvular heart disease remains unknown.
Is non-alcoholic fatty liver disease (NAFLD) associated with an increased risk of valvular heart disease?
Is non-alcoholic fatty liver disease (NAFLD) associated with an increased risk of valvular heart disease?
Non-alcoholic fatty liver disease is independently associated with a significantly higher prevalence of valvular heart disease, suggesting a potential structural cardiovascular impact of the condition.
NAFLD may warrant valvular evaluation in at-risk patients; leaves open causality and need for prospective confirmation.
BACKGROUND: Non-alcoholic fatty liver (NAFLD) disease has become the commonest cause of end-stage liver disease. Patients with NAFLD have an increased risk of associated extrahepatic conditions, including structural and functional cardiovascular disease. Still, it is unknown if there is an association between NAFLD and valvular heart disease (VHD). The aim of this paper was to determine the association between NAFLD and VHD. METHODS: We performed a single center retrospective study in EMMS Nazareth Hospital from April 2010 to April 2018. All patients who were diagnosed with NAFLD and who had an echocardiography performed within one year were included. Subjects age and sex-matched, who had echocardiography performed in the same period were included in the control group. RESULTS: The mean age of the NAFLD group was 41.5±11.7 vs. 42.8±10.8 years of the control group (P=0.2). The prevalence of aortic stenosis, aortic insufficiency, mitral stenosis and mitral insufficiency were significantly higher in NAFLD patients compared to the control group (1.2% vs. 0.22%, 1.32% vs. 0.32%, 0.66% vs. 0.27%, and 1.87% vs. 0.41%, respectively; P<0.001). In the multivariate logistic regression analysis, NAFLD was found to be independent risk factor for VHD (OR 2.39, 95% CI 2.17-2.78, P<0.001). CONCLUSIONS: VHD was significantly seen more frequently in NAFLD patients compared to controls. Prospective studies are needed to validate our findings and to elucidate the pathogenesis of VHD in patients with NAFLD.
No takes yet. Share an insight, caveat, or question.
Mari et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: